StockData
Geron Corp logo

Geron Corp (GERN) company profile

GERNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 2/30
$1.00+0.06 (+6.17%)

Close on Nov 17, 2026Market cap $642.47MP/E –Yield –

About Geron

Pharmaceutical Preparations, SIC 2834

Geron Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutics for hematologic malignancies. Its primary product is RYTELO (imetelstat), an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. In addition to commercializing RYTELO, the company conducts clinical research and development, including advanced clinical trials such as the IMpactMF Phase 3 study evaluating imetelstat in patients with relapsed or refractory myelofibrosis. Geron's operations serve eligible patients, healthcare providers, and clinical trial participants across specialized oncology care.

The company conducts commercial activities and clinical programs in the United States and works to expand the availability of its therapies internationally, including within the European Union. Geron operates through wholly owned subsidiaries located in the United Kingdom and the Netherlands. The company maintains its corporate headquarters and principal executive offices in Foster City, California, alongside leased office facilities in New Jersey.

Summary of the business section of Geron's latest annual report, written by StockData.

Company profile

Company

Legal name
Geron Corp
Founded
1990
Headquarters
Foster City, CA
Address
919 East Hillsdale Boulevard, Suite 250 94404
Phone
(650) 473-7700
Employees
42, Dec 31, 2014
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Iselin, New Jersey

Stock & identifiers

Ticker
GERN
Exchange
Nasdaq
IPO date
Jul 31, 1996
Shares outstanding
642M, Jul 31, 2026
Public float
$860.50M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
886744
CUSIP
374163103
ISIN
US3741631036
FIGI
BBG000GX1891
Share class FIGI
BBG001S6TSX4
LEI
549300T282D7Z2YESL90
EIN
75-2287752

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Harout SemerjianPresident & CEO, Director53,500
John A. ScarlettChairman, President and CEO, Director137,500
Timothy WilliamsEVP and Chief Legal Officer12,000
Michelle RobertsonEVP, CHIEF FINANCIAL OFFICER27,500
Joseph EidEVP, R&D; Chief Medical Office–
Ahmed ElNawawiEVP, Chief Commercial Officer10,000
James ZieglerEVP, Chief Commercial Officer100,000
Scott Alan SamuelsEVP, Chief Legal Officer26,682
Andrew J. GrethleinEVP, Chief Operating Officer676,615
Robert J. SpiegelDirector212,161
Dawn Carter BirDirector–
Elizabeth G. O'FarrellDirector33,627
Susan MolineauxDirector165,527
John F. McDonaldDirector–
Constantine ChinoporosDirector–
Patricia S. AndrewsDirector–
V. Bryan LawlisDirector13,300
Gaurav AggarwalDirector1,970

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Dawn Bir
$522.12K$243.25K$2.37M$83$125
FY2025
Harout Semerjian
$10.22M$10.18M$2.37M$83$125
FY2025
John Scarlett
$7.42M-$7.33M$2.37M$83$125
FY2024$6.15M$15.29M$4.66M$223$93
FY2023$4.95M$4.47M$2.85M$133$94
FY2022$3.00M$5.90M$1.36M$152$90

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Harout Semerjian
President and Chief Executive Officer (as of August 7, 2025)
$321.54K––$9.70M$203.00K$1.82K$10.22M–
John A. Scarlett, M.D.
Former Chairman of the Board, President and Chief Executive Officer
$309.78K–$1.08M$4.31M–$1.73M$7.42M+21%
Dawn C. Bir
Former Interim President and Chief Executive Officer (as of March 17, 2025)
$318.19K––$163.67K–$40.26K$522.12K–
Michelle J. Robertson
Executive Vice President, Finance, Chief Financial Officer, Treasurer and Interim Secretary
$559.80K–$289.30K$1.15M$239.30K$11.45K$2.25M+5%
Ahmed ElNawawi
Executive Vice President, Chief Commercial Officer (as of October 20, 2025)
$107.69K$200.00K–$2.57M–$242$2.88M–
Joseph Eid, M.D.
Executive Vice President, Research & Development, Chief Medical Officer (as of November 11, 2024)
$650.00K–––$339.60K$11.45K$1.00M-87%
Andrew J. Grethlein, Ph.D.
Former Executive Vice President, Chief Operating Officer
$563.28K–$368.20K$1.47M–$910.72K$3.32M-54%
James Ziegler
Former Executive Vice President, Chief Commercial Officer (as of September 9, 2024)
$470.03K–$234.07K$927.55K–$761.06K$2.39M-59%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2014, we had 42 employees, of whom 7 hold Ph.D.”

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 7, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 8, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 1, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 12, 2009Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 5, 2005Name changeName changed from GERON CORPORATION to Geron Corp
Jul 31, 1996IPOInitial public offering priced (424B4 prospectus)

See a number that looks wrong?